This guidance clarifies the expectations on the application of the further pharmacovigilance provisions set out within the updated CIR 520/2012 for UK authorised products.
Similar Posts
Blood: authorisations and safety reporting
Information about ensuring blood and blood component safety.
Medical devices: get regulatory advice from the MHRA
How to apply for a regulatory advice meeting on medical devices and in vitro diagnostic devices.
Clinical trials for medicines: apply for approval in the UK
How to apply for a clinical trial from 28 April 2026, including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Guidance: Herbal medicines granted a traditional herbal registration (THR)
A list of herbal medicines currently holding a traditional herbal registration (THR) granted by the Medicines and Healthcare products Regulatory Agency (MHRA).
MHRA phase I accreditation scheme
How to join the phase I accreditation scheme.
Guidance: GLP-1 medicines for weight loss and diabetes: what you need to know
Guidance on the safe and effective use of GLP-1 medicines for weight loss and diabetes.